Lilly Australia’s Strattera Under Fire By Ethics Panel Disclosure
This article was originally published in PharmAsia News
An ethics committee said an Australian university was misled by a researcher when it agreed to a study of Strattera (atomoxetine), Eli Lilly Australia's treatment for attention deficit hyperactivity disorder. The ethics committee of Curtin University said the school relied on a researcher who told it the U.S. FDA had canceled a black box warning for the drug based on an increased risk of suicidal thoughts. The university, in turn, failed to disclose the extent of Lilly's involvement in the ADHD study it was conducting. The disclosures led some members of Parliament to call for a ban on the drug because of safety questions, but the government rejected the idea. One Parliament member said the Therapeutic Goods Administration had received 18 reports of suicidal thoughts after taking Strattera, among 56 reports of adverse reactions. (Click here for more
You may also be interested in...
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.